| Rate of mAb-tumor cell complex formation |
for cetuximab
for panitumumab | mg cell−1 L−1 day−1 | [32] |
| Concentration of cetuximab or panitumumab for half-maximal EGFR binding |
for cetuximab
for panitumumab | mg L−1 | [32] |
| Carrying capacity of wild-type and mutant tumor cells combined in the absence of tumor angiogenesis |
| cells | [50] |
| Conversion factor from number of activated endothelial cells to the increase in tumor carrying capacity | 1 |
| Est. |
| Maximum rate of production of TGF-β by hypoxic tumor cells |
| IU L−1 day−1 | Est. from [50] |
| Critical tumor size at which the angiogenic switch occurs |
| cells | [50] |
| Concentration of TGF-β necessary to reduce the CD8+ T cell killing rate of tumor cells by half |
| IU L−1 | [51] |
| Decay rate of TGF-β | 10 | day−1 | [50] |
| Proliferation rate of angiogenic endothelial cells | 0.198 | day−1 | [52] |
| Maximum carrying capacity for blood vessel growth stimulated by TGF-β secreted by tumor cells |
| cells | Est. |
| TGF-β concentration that gives a half-maximal proliferation rate of endothelial cells |
| IU L−1 | Est. |
| Growth inhibition coefficient of endothelial cells by tumor cells |
| cell−2/3 day−1 | Est. from [53] |
| Suppressive effect of Treg cells on wild-type and mutant tumor cell kill rate by NK cells |
| L cell−1 | [45] |
w | Rate of Treg cell production from circulating lymphocytes |
| day−1 | [45] |
| Rate of Treg cell turnover |
| day−1 | [54] |
| Rate of IL-2-induced Treg cell proliferation |
| day−1 | [49] |
| Concentration of IL-2 necessary for half-maximal activation of Treg cells | 11.027 | IU L−1 | [49] |